Clinical trials: Genes, erbB-1
Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and clinical activity of etrumadenant (AB928) in combination…
- Conditions
- Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation
- Trial name
- ARC-4 (NCT03846310)
- Testing
- Etrumadenant, Zimberelimab, Carboplatin
- Where
- 22 sites in United States, Singapore and 2 more
- Volunteers
- 77 people
- Sponsor
- Arcus Biosciences, Inc.
Non-Small Cell Lung Cancer
Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific
A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Asia Pacific Patients with Locally Advanced/Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal…
- Trial name
- AURA17 (NCT02442349)
- Testing
- AZD9291
- Where
- 30 sites in Australia, China and 1 more
- Volunteers
- 171 people
- Sponsor
- AstraZeneca
EGFR Gene Mutation
EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC
The aim of this study was to compare the efficacy of EGFR-TKIs(Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors) treatment plus concurrent chemotherapy versus sequential treatment with EGFR-TKIs and chemotherapy in…
- Trial name
- effect (NCT02886195)
- Testing
- pemetrexed, cisplatin, Erlotinib
- Volunteers
- 120 people
- Sponsor
- Fujian Cancer Hospital
Lung Cancer, Non-small Cell Lung Cancer
Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene
The purpose of this research study is to: see if gefitinib pills can shrink Stage 1 or 2 non-small cell lung cancers before surgery see if your non-small cell lung cancer has a mutation in a certain part of the EGFR gene see if…
- Conditions
- Lung Cancer, Non-small Cell Lung Cancer, Bronchioloalveolar Cancer
- Trial name
- NCT00588445
- Testing
- Gefitinib
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Small Cell Lung Cancer
Mutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With Erlotinib
Recently it has been suggested that specific mutations in the EGFR gene in lung cancer patients is associated with response to a novel drug targeting the EGF system.
- Trial name
- NCT00815971
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Aarhus University Hospital
Solid Tumors, Advanced Cancer
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
To assess: efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion…
- Conditions
- Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer
- Trial name
- SPARTA (NCT03175224)
- Testing
- APL-101 Oral Capsules
- Where
- 35 sites in United States, Australia and 9 more
- Volunteers
- 497 people
- Sponsor
- Apollomics Inc.
Non Small Cell Lung Cancer, EGF-R Positive Non-Small Cell Lung Cancer
The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib
This is an observational, non-interventional, single-country, multi center, retrospective cohort study, based on real world data collection, of patients with locally advanced or metastatic Epidermal Growth Factor Receptor (EGFR)…
- Conditions
- Non Small Cell Lung Cancer, EGF-R Positive Non-Small Cell Lung Cancer, EGFR Gene Mutation
- Trial name
- NCT04640870
- Testing
- Afatinib
- Volunteers
- 59 people
- Sponsor
- Hellenic Cooperative Oncology Group
Lung Cancer, Non-small Cell, EGFR T790M
Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer
Almonertinib Plus Pemetrexed and Carboplatin Versus Almonertinib Alone in Advanced NSCLC With EGFR T790M After First- or Second-generation TKIs Therapy: a Randomized, Controlled, Open-label, Phase 2 Study
- Conditions
- Lung Cancer, Non-small Cell, EGFR T790M, EGFR Gene Mutation
- Trial name
- APPEAL (NCT04592666)
- Testing
- Almonertinib, Pemetrexed, Carboplatin
- Where
- China
- Volunteers
- 226 people
- Sponsor
- Fudan University
EGFR Gene Mutation, Lung Cancer
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.
The purpose of this study is to assess whether dacomitinib after osimertinib is effective in participants with metastatic EGR-mutant lung cancers.
- Conditions
- EGFR Gene Mutation, Lung Cancer, Lung Cancer Metastatic
- Trial name
- NCT03755102
- Testing
- Dacomitinib, Osimertinib
- Where
- 8 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer, EGFR Gene Mutation
Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment
This is a prospective, multi-center, single-arm clinical trial to evaluate the safety and effectiveness of Almonertinib treatment in patients with EGFR mutation positive and advanced non-small cell lung cancer (NSCLC) who are…
- Trial name
- ACTIVE (NCT04882345)
- Testing
- Almonertinib
- Volunteers
- 40 people
- Sponsor
- Shanghai Chest Hospital
Advanced Non-Squamous Non-Small Cell Lung Cancer
Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation
To compare the differential influence of 1st line doublet chemotherapy containing Docetaxel versus Pemetrexed on clinical efficacy of Erlotinib as a second line therapy in patients with relapsed or progressed non-squamous NSCLC.
- Trial name
- NCT01204307
- Testing
- Docetaxel/cisplatin, Pemetrexed/cisplatin
- Where
- 4 sites in Taiwan
- Volunteers
- 101 people
- Sponsor
- Chang Gung Memorial Hospital
Non-small Cell Lung Cancer, EGFR Gene Mutation
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
The purpose of this study is to evaluate the efficacy and safety of Nintedanib with EGFR-TKI in participants with advanced EGFR-TKI-resistant non-small cell lung cancer
- Conditions
- Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation
- Trial name
- NCT06071013
- Testing
- Nintedanib, gefitinib, erlotinib, afatinib, osimertinib
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- China Medical University Hospital
Lung Adenocarcinoma
A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test
This project aims to do a small sample exploratory study, to predict EGFR-TKI targeted therapy gefitinib' s efficacy in late stage lung adenocarcinoma patients (phase IIIB or IV), who have negative tissue EGFR gene mutation…
- Trial name
- NCT02738684
- Volunteers
- 100 people
- Sponsor
- Southwest Hospital, China